A Phase 2 interventional study of CBP-201 and Placebo in Moderate-to-severe Atopic Dermatitis, sponsored by Connect Biopharm LLC. Completed at 48 sites in China. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-01.
Sponsored by Connect Biopharm LLC · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.
Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 52nd largest by enrollment of the 190 interventional ones that give a count, is one of 13 that started in 2021, is one of 58 in phase 2, and was the 34th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:
Galderma R&D · Sites in China
Ages 12+
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Sites in China
Ages 18–75
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Sites in China
Ages 2–11
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 18–75
QuantX Biosciences, Inc. · Sites in China
Ages 18 mo–65 yrs · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 12 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
206 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 53 · Phase 2 76 · Phase 3 63 · Phase 4 5
First in 2011; this study’s year is marked. 13 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 330 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 164 across the 190 interventional studies, 472 across the 16 observational. Of the 114 that completed or were terminated, 22 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
183 of 206 have an industry lead sponsor. The 10 most frequent:
Connect Biopharm LLC is the lead sponsor of 11 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.
Connect Biopharm LLC has 4 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
27 of the studies in Dermatitis, Atopic with a site in China that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06775860Phase 3Beijing InnoCare Pharma Tech Co., Ltd.ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis | 2026-11-25 |
| NCT07540442Phase 3Shanghai Mabgeek Biotech.Co.LtdA Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis | 2027-01-05 |
| NCT07106372Phase 3Keymed Biosciences Co.LtdA Study of Stapokibatrt in Children Subjects With Atopic Dermatitis | 2027-02 |
| NCT06880276Phase 3Qilu Pharmaceutical Co., Ltd.Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis | 2027-03 |
| NCT07386743Phase 3Jiangsu Genscend Biopharmaceutical Co., LtdA Phase III Study of GS101 Injection to Dupixent® | 2027-04 |
Add all 27 to your calendar (.ics) → With an account.
Among the 206 studies in Dermatitis, Atopic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of CBP-201 in Chinese subjects with moderate to severe atopic dermatitis.
This study is a randomized, double-blind, multi-center, controlled study designed to assess the efficacy, safety and PK characteristics of CBP-201 in eligible subjects with moderate to severe AD.
The study includes a screening period, a treatment period and a follow-up period. The treatment period is divided into two stages.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosed with atopic dermatitis (according to the American Academy of Dermatology's Guidelines of care for the management of atopic dermatitis, 2014[1]) at the screening, visit and:
a) The subject has been suffering from the disease for more than 1 year at the time of screening, and according to the judgment of the investigator, the subject has had poor response to topical drugs such as , phosphodiesterase-4 (PDE-4) inhibitors or calcineurin inhibitors (TCI), or it is not medically suitable for the subject to receive topical drug treatment (e.g., there are important side effects or safety risks);
Note: Poor response is defined as any of the following conditions:
i. The patient has not achieved and maintained response or reached a low disease activity state (equivalent to IGA 0=asymptomatic to 2=mild) despite regular use of topical therapy during the 1 year before baseline; ii. The patient has received systemic treatment for AD despite regular use of topical therapy during the 1 year before baseline.
b. At the screening and baseline visit, Investigator's Global Assessment (IGA) score ≥3 (according to the validated Investigator Global Assessment for Atopic Dermatitis [vIGA-AD™] scale, see Section 17.4 Appendix D), Eczema Area and Severity Index (EASI) score≥16 (see Section 17.5, Appendix E), and≥10% body surface area (BSA) of AD involvement(see Section 17.6, Appendix F); c. The average score of the maximum pruritus intensity in the Peak Pruritus Numerical Rating Scale (PP-NRS) ≥4 (see Section 17.1, Appendix A).
Note: The baseline average score of maximum pruritus intensity in the PP-NRS will be calculated based on the average value of the maximum pruritus intensity in the PP-NRS score [daily score range 0-10] every day within 7 days before randomization. In these 7 days, the scores of at least 4 days are required for the calculation of the baseline average score. If the patient's reporting days are less than 4 days in the 7 days before the planned date of randomization, randomization should be postponed until the requirements are met, but it is not allowed to exceed the maximum screening period of 28 days.
Female subjects of (FCBP) and male subjects who have not undergone vasectomy must take highly effective measures during the entire study period, including the 8-week follow-up period after discontinuation of study drug. women (determined by testing follicle stimulating hormone [FSH]) and women with a record of surgical sterilization (i.e., tubal ligation or hysterectomy or bilateral oophorectomy) before the screening visit can be considered infertile.
Highly effective contraceptive measures include:
i. Abstinence (acceptable only if it is part of the subject's routine lifestyle); ii. Hormones (oral, patch, ring, injection, implant) combined with male condoms. This measure must be used at least 30 days before the first study drug administration. Otherwise, another acceptable method of contraception must be used; iii. Intrauterine device (IUD) combined with male condoms; iv. Exceptions are: a) women who have had amenorrhea for at least 12 consecutive months without using drugs known to cause amenorrhea, and have a recorded FSH level greater than 40 mIU/mL or in the postmenopausal range; or b) surgical sterilization (e.g., hysterectomy, bilateral oophorectomy).
Exclusion Criteria:
Patients who have received any of the following treatments:
Eligibility criteria Inclusion criteria
Patients must meet all of the following criterias to be enrolled into this study:
Patients who meet any of the following:
Note:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CBP-201 Dose subcutaneous (SC) injection
Drug: CBP-201
subcutaneous (SC) injection
Drug: Placebo
CBP-201 subcutaneous(SC) injection.
subcutaneous(SC) injection
Investigator Global Assessment (IGA) (0-1)
The percentage of subjects whose IGA score is 0-1 and decreased by ≥2 points The Validated Investigator Global Assessment for AD (vIGA-AD™) Scale is a 5-point classification scale based on the overall appearance of the skin lesions at a specific time point (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).
Time frame: Baseline to Week16
Eczema Area and Severity Index (EASI)-75
The percentage of subjects achieving EASI-75 (EASI score is decreased by ≥75% from baseline) The total EASI score ranges from 0 (lowest) to 72 (highest); the higher the score, the higher the severity of AD (more severe).
Time frame: Baseline to Week16
Change in Peak Pruritus Numerical Rating Scale(PP-NRS) (Decreased by ≥ 4 Points)
The percentage of subjects whose weekly average PP-NRS is decreased by ≥ 4 points The score ranges from 0 to 10, in which 0 represents "no pruritus" and 10 "worst imaginable pruritus".
Time frame: Baseline to Week16
Change in Peak Pruritus Numerical Rating Scale(PP-NRS) (Decreased by ≥ 3 Points)
The percentage of subjects whose weekly average PP-NRS is decreased by ≥ 3 points The score ranges from 0 to 10, in which 0 represents "no pruritus" and 10 "worst imaginable pruritus".
Time frame: Baseline to Week16
Change in the Weekly Average Peak Pruritus Numerical Rating Scale(PP-NRS)
Change in the weekly average PP-NRS The score ranges from 0 to 10, in which 0 represents "no pruritus" and 10 "worst imaginable pruritus".
Time frame: Baseline to Week16
Eczema Area and Severity Index (EASI)-90
The percentage of subjects achieving EASI-90 (EASI score is decreased by ≥90% from baseline) The total EASI score ranges from 0 (lowest) to 72 (highest); the higher the score, the higher the severity of AD (more severe).
Time frame: Baseline to Week16
Percentage Change in the Weekly Average Peak Pruritus Numerical Rating Scale(PP-NRS)
Percentage change in the weekly average PP-NRS The score ranges from 0 to 10, in which 0 represents "no pruritus" and 10 "worst imaginable pruritus".
Time frame: Baseline to Week16
| Milestone | Group A: CBP-201 300mg Q2W | Group B: Placebo Q2W | Group C: Double-blinded CBP-201 300mg Q2W | Group D: Double-blinded CBP-201 300mg Q4W | Group E: Open-Label CBP-201 300mg Q2W |
|---|---|---|---|---|---|
| Started | 219 | 111 | 0 | 0 | 0 |
| Completed | 209 | 102 | 0 | 0 | 0 |
| Not completed | 10 | 9 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 8 | 6 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Poor compliance | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 |
| Milestone | Group A: CBP-201 300mg Q2W | Group B: Placebo Q2W | Group C: Double-blinded CBP-201 300mg Q2W | Group D: Double-blinded CBP-201 300mg Q4W | Group E: Open-Label CBP-201 300mg Q2W |
|---|---|---|---|---|---|
| Started | 0 | 0 | 113 | 112 | 86 |
| Completed | 0 | 0 | 107 | 99 | 73 |
| Not completed | 0 | 0 | 6 | 13 | 13 |
| Withdrew: Withdrawal by subject | 0 | 0 | 6 | 9 | 11 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Covid-19 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 1 |
The percentage of subjects whose IGA score is 0-1 and decreased by ≥2 points The Validated Investigator Global Assessment for AD (vIGA-AD™) Scale is a 5-point classification scale based on the overall appearance of the skin lesions at a specific time point (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).
| percentage of participants | Group A: CBP-201 300mg Q2W | Group B: Placebo Q2W |
|---|---|---|
| Investigator Global Assessment (IGA) (0-1) | 29.0 (23.0 to 35.0) | 5.9 (1.4 to 10.4) |
The percentage of subjects achieving EASI-75 (EASI score is decreased by ≥75% from baseline) The total EASI score ranges from 0 (lowest) to 72 (highest); the higher the score, the higher the severity of AD (more severe).
| percentage of participants | Group A: CBP-201 300mg Q2W | Group B: Placebo Q2W |
|---|---|---|
| Eczema Area and Severity Index (EASI)-75 | 58.6 (51.9 to 65.3) | 22.6 (14.5 to 30.7) |
The percentage of subjects whose weekly average PP-NRS is decreased by ≥ 4 points The score ranges from 0 to 10, in which 0 represents "no pruritus" and 10 "worst imaginable pruritus".
| percentage of participants | Group A: CBP-201 300mg Q2W | Group B: Placebo Q2W |
|---|---|---|
| Change in Peak Pruritus Numerical Rating Scale(PP-NRS) (Decreased by ≥ 4 Points) | 36.3 (29.7 to 42.8) | 10.5 (4.5 to 16.5) |
The percentage of subjects whose weekly average PP-NRS is decreased by ≥ 3 points The score ranges from 0 to 10, in which 0 represents "no pruritus" and 10 "worst imaginable pruritus".
| percentage of participants | Group A: CBP-201 300mg Q2W | Group B: Placebo Q2W |
|---|---|---|
| Change in Peak Pruritus Numerical Rating Scale(PP-NRS) (Decreased by ≥ 3 Points) | 50.0 (43.2 to 56.9) | 20.3 (12.7 to 28.0) |
Change in the weekly average PP-NRS The score ranges from 0 to 10, in which 0 represents "no pruritus" and 10 "worst imaginable pruritus".
| score on a scale | Group A: CBP-201 300mg Q2W | Group B: Placebo Q2W |
|---|---|---|
| Change in the Weekly Average Peak Pruritus Numerical Rating Scale(PP-NRS) | -2.95 (-3.28 to -2.62) | -0.99 (-1.46 to -0.53) |
The percentage of subjects achieving EASI-90 (EASI score is decreased by ≥90% from baseline) The total EASI score ranges from 0 (lowest) to 72 (highest); the higher the score, the higher the severity of AD (more severe).
| percentage of participants | Group A: CBP-201 300mg Q2W | Group B: Placebo Q2W |
|---|---|---|
| Eczema Area and Severity Index (EASI)-90 | 33.4 (27.0 to 39.8) | 6.4 (1.4 to 11.4) |
Percentage change in the weekly average PP-NRS The score ranges from 0 to 10, in which 0 represents "no pruritus" and 10 "worst imaginable pruritus".
| percentage change of PP-NRS value | Group A: CBP-201 300mg Q2W | Group B: Placebo Q2W |
|---|---|---|
| Percentage Change in the Weekly Average Peak Pruritus Numerical Rating Scale(PP-NRS) | -40.00 (-44.80 to -35.20) | -13.50 (-20.19 to -6.82) |
Collected over Stage 1 treatment period (Day1~Week16) - Stage 2 treatment period (Week16~Week52) - Follow-up period (Week53~Week60). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A: CBP-201 300mg Q2W | 0/219 (0%) | 1/219 (0.5%) | 80/219 (36.5%) |
| Group B: Placebo Q2W | 0/111 (0%) | 3/111 (2.7%) | 34/111 (30.6%) |
| Group C: Double-blinded CBP-201 300mg Q2W | 0/113 (0%) | 1/113 (0.9%) | 70/113 (61.9%) |
| Group D: Double-blinded CBP-201 300mg Q4W | 0/112 (0%) | 3/112 (2.7%) | 67/112 (59.8%) |
| Group E: Open-Label CBP-201 300mg Q2W | 0/85 (0%) | 6/85 (7.1%) | 53/85 (62.4%) |
| Event | Group A: CBP-201 300mg Q2W | Group B: Placebo Q2W | Group C: Double-blinded CBP-201 300mg Q2W | Group D: Double-blinded CBP-201 300mg Q4W | Group E: Open-Label CBP-201 300mg Q2W |
|---|---|---|---|---|---|
| Cardiac disordersCardiac disorders | 0/219 | 0/111 | 0/113 | 0/112 | 2/85 |
| Injury,poisoning and procedural complicationsInjury, poisoning and procedural complications | 1/219 | 2/111 | 0/113 | 0/112 | 1/85 |
| Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders | 1/219 | 1/111 | 0/113 | 1/112 | 1/85 |
| Infections and infestationsInfections and infestations | 0/219 | 0/111 | 1/113 | 0/112 | 1/85 |
| Endocrine disordersEndocrine disorders | 0/219 | 0/111 | 0/113 | 0/112 | 1/85 |
| Eye disordersEye disorders | 0/219 | 0/111 | 0/113 | 0/112 | 1/85 |
| Gastrointestinal disordersGastrointestinal disorders | 0/219 | 1/111 | 0/113 | 1/112 | 0/85 |
| Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders | 0/219 | 0/111 | 0/113 | 1/112 | 0/85 |
| Vascular disordersVascular disorders | 0/219 | 0/111 | 1/113 | 0/112 | 0/85 |
| Event | Group A: CBP-201 300mg Q2W | Group B: Placebo Q2W | Group C: Double-blinded CBP-201 300mg Q2W | Group D: Double-blinded CBP-201 300mg Q4W | Group E: Open-Label CBP-201 300mg Q2W |
|---|---|---|---|---|---|
| COVID-19Infections and infestations | 0/219 | 0/111 | 38/113 | 34/112 | 21/85 |
| Atopic DermatitisSkin and subcutaneous tissue disorders | 23/219 | 19/111 | 14/113 | 27/112 | 14/85 |
| upper respiratory infectionInfections and infestations | 14/219 | 7/111 | 12/113 | 12/112 | 15/85 |
| HyperlipidaemiaMetabolism and nutrition disorders | 23/219 | 6/111 | 3/113 | 8/112 | 5/85 |
| hyperuricemiaMetabolism and nutrition disorders | 21/219 | 5/111 | 7/113 | 3/112 | 3/85 |
| FeverGeneral disorders | 0/219 | 0/111 | 9/113 | 9/112 | 7/85 |
| conjunctivitisInfections and infestations | 0/219 | 0/111 | 4/113 | 3/112 | 6/85 |
| Tested positive for SARS-CoV-2Infections and infestations | 0/219 | 0/111 | 4/113 | 7/112 | 2/85 |
| urinary tract infectionInfections and infestations | 0/219 | 0/111 | 5/113 | 6/112 | 5/85 |
| Elevated alanine aminotransferaseInjury, poisoning and procedural complications | 0/219 | 0/111 | 4/113 | 2/112 | 5/85 |
| Age, Continuous(years) | Group A: CBP-201 300mg Q2W | Group B: Placebo Q2W | Total |
|---|---|---|---|
| Mean | 38.6 ± 16.65 | 39.6 ± 17.54 | 38.9 ± 16.93 |
| Sex: Female, Male(Participants) | Group A: CBP-201 300mg Q2W | Group B: Placebo Q2W | Total |
|---|---|---|---|
| Female | 73 | 40 | 113 |
| Male | 146 | 71 | 217 |
| Race (NIH/OMB)(Participants) | Group A: CBP-201 300mg Q2W | Group B: Placebo Q2W | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 219 | 111 | 330 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| BMI(kg/m^2) | Group A: CBP-201 300mg Q2W | Group B: Placebo Q2W | Total |
|---|---|---|---|
| Mean | 23.66 ± 3.932 | 24.98 ± 4.829 | 24.10 ± 4.293 |
| Severity of Atopic Dermatitis at Baseline(Participants) | Group A: CBP-201 300mg Q2W | Group B: Placebo Q2W | Total |
|---|---|---|---|
| Moderate (IGA=3) | 99 | 50 | 149 |
| Severe (IGA=4) | 120 | 61 | 181 |
| EASI at Baseline(units on a scale) | Group A: CBP-201 300mg Q2W | Group B: Placebo Q2W | Total |
|---|---|---|---|
| Mean | 29.27 ± 11.658 | 28.62 ± 12.092 | 29.05 ± 11.791 |
| PP-NRS at Baseline(units on a scale) | Group A: CBP-201 300mg Q2W | Group B: Placebo Q2W | Total |
|---|---|---|---|
| Mean | 7.19 ± 1.680 | 7.17 ± 1.459 | 7.18 ± 1.607 |
| BSA at Baseline(units on a scale) | Group A: CBP-201 300mg Q2W | Group B: Placebo Q2W | Total |
|---|---|---|---|
| Mean | 48.55 ± 20.666 | 46.64 ± 21.581 | 47.91 ± 20.965 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2021 to primary completion in Dec 2022, 15 months.
Results were first posted in May 2024, 1 year 5 months after primary completion.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 15 months is above that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CBP-201
Connect Biopharm LLC